Cover Image
市場調查報告書

美國的經皮吸收貼片市場預測

US Transdermal Patch Market Outlook 2020

出版商 KuicK Research 商品編碼 363933
出版日期 內容資訊 英文 370 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
美國的經皮吸收貼片市場預測 US Transdermal Patch Market Outlook 2020
出版日期: 2016年07月21日 內容資訊: 英文 370 Pages
簡介

美國,經皮吸收貼片的消費群極高,女性用避孕藥,尼古丁替代療法 (NRT) 等,這數年多變得引人注目。

本報告提供美國的經皮吸收貼片市場相關調查分析,市場概要,非專利/品牌經皮吸收貼片,價值鏈分析,醫藥品受託製造廠商 (CMO),臨床實驗平台分析,臨床實驗平台,前臨床階段的主要產品,已上市產品等系統性資訊。

第1章 所謂經皮吸收貼片

第2章 經皮吸收貼片的分類

  • 單層/多層式的藥物黏劑
  • Reservoir型的經皮吸收貼片
  • 矩陣型的經皮吸收貼片
  • 蒸氣貼片
  • 主動/被動貼片

第3章 經皮吸收貼片的必要性

第4章 經皮吸收貼片的藥物輸送機制

  • 經皮治療的特性
  • 經皮吸收貼片的結構要素
  • 暈車、尼古丁、女性用避孕藥貼片的機制

第5章 經皮吸收貼片 vs. 傳統的藥物輸送手法

第6章 美國的經皮吸收貼片市場概要

  • 目前市場方案
  • 美國的經皮吸收貼片臨床實驗平台概要

第7章 非專利/品牌經皮吸收貼片

第8章 經皮吸收貼片市場價值鏈分析

  • 研究開發
  • 製造
  • 行銷、流通
  • 終端用戶價格

第9章 美國的經皮吸收貼片CMO

第10章 美國的經皮吸收貼片市場機會的評估

  • 帕金森氏症
  • 老年癡呆症
  • 女性用避孕藥
  • 尼古丁替代療法 (NRT)
  • 胰島素
  • 疫苗

第11章 美國的經皮吸收貼片市場動態

  • 可喜的市場參數
  • 商業化的課題

第12章 美國的經皮吸收貼片市場未來發展預測

第13章 美國的經皮吸收貼片臨床實驗平台:各企業,各適應症,各相位

  • 研究階段
  • 前臨床階段
  • 第一階段
  • 第一階段/第二階段
  • 第二階段
  • 第二階段/第三階段
  • 第三階段
  • 已申請
  • 已通過核准

第14章 已上市的經皮吸收貼片臨床分析:各企業,各適應症

第15章 開發中止/中斷的美國的經皮吸收貼片臨床分析

  • 沒有開發報告
  • 中止
  • 市場撤退

第16章 競爭情形

  • 3M Pharmaceuticals
  • Acrux
  • Agile Therapeutics
  • Allergan
  • ANI Pharmaceuticals
  • Antares Pharma
  • Bayer HealthCare Pharmaceuticals
  • Corium International
  • Chase Pharmaceuticals
  • DURECT Corporation
  • Endo Pharmaceuticals
  • Fempharm
  • 久光製藥
  • Immune Pharmaceuticals
  • Imprimis Pharmaceuticals
  • Ipsen Bioscience
  • Johnson & Johnson
  • LaSalle Laboratories
  • Lavipharm-increase
  • MINRAD International
  • NeurogesX
  • Noven Pharmaceuticals
  • NuPathe
  • Nuvo Research
  • Novartis
  • Pain Therapeutics
  • ProStrakan
  • Purdue Pharma
  • Sanofi
  • Scilex Pharmaceuticals
  • 千壽製藥
  • Somerset Pharmaceuticals
  • 帝國製藥
  • Therapeutic Discovery Corporation
  • Transdermal Delivery Solutions
  • UCB
  • Xel Pharmaceuticals
  • Zosano Pharma

圖表

目錄

The last two decades have witnessed rapid growth in multiple innovations and commercialization of new medicinal agents and drug delivery mechanism. These innovations in drug delivery systems have not only enabled the successful implementation of many of these novel pharmaceuticals products such as transdermal patches, but have also permitted the development of new medical treatments with existing drugs. The need of more innovation in field of transdermal drug delivery system is still huge and will remain so in the upcoming years of the medicinal world.

If taken a look at the medicinal markets of the world, indeed they are now replete with medications designed to ease and cure the symptoms associated with thousands of conditions. Traditional medication delivery methods, such as pills, capsules, liquids, powders, and intravenous needles, are often inefficient or invasive and can lead to undesirable side effects.

Amongst the newer methodologies for administration of medicines is the use of transdermal approaches, including gels and patches for the treatment of many of the more common ailments. The creation of transdermal delivery systems has been one of the most important innovations, offering a number of advantages over the oral route.

Transdermal patches comprise a method of delivering medication through the skin in a non-invasive manner. During transdermal drug delivery, a patch is simply applied on the epidermal layer of a patient's skin. The patch is modulated to contain the medication prescribed to the patient and is designed in such a way that the medication permeates the skin in a controlled fashion thus attaining more steady levels of the drug in the body.

Transdermal patches presently donning the market are formulated in accordance with requirement of the medicinal therapy. They can be worn for as low as 8 hours to as long as 7 days depending on the therapeutic indication. These patches are secured with adhesives, which are designed to adhere comfortably to the skin which in turn allows a patient to use the patches for as long as is indicated by his or her physician. Transdermal drug delivery provides excellent control of the rate of delivery directly into the bloodstream. It also offers a predictable pharmacokinetic profile and constant drug levels over extended periods of time without the extreme peak/trough fluctuations inherent in oral administration with the inherent power of discontinuation of therapy immediately by simply removing the patch.

The market for transdermal products has skyrocketed since its innovation and is likely to continue for the foreseeable future. An increasing number of Transdermal drug delivery (TDD) products continue to deliver real therapeutic benefit to patients around the world. The FDA approved a total of 32 transdermal products over the past 20 years, the majority of which use passive transport that allows the drug to be continually absorbed into the skin via natural processes.

Technologies behind transdermal patches are improving continuously and have been introduced for different indication in US. They have been introduced for new indications for which no transdermal product was available allowing them to occupy major market shares. Increase in demand for better therapeutics at affordable prices is expected to be the main factor behind their growth in US market. Improved material science, advanced manufacturing capabilities and high acceptance rates will further propel growth in this segment. However, some immediate issues like lesser coverage of indications have yet to be overcome in coming years. Another issue is technology related, which has definitely improved, but needs to be improved in order to come forth with diseases like HIV infection. Overall, transdermal patch market in US is expected to grow continuously reflecting optimistic future.

“US Transdermal Patch Market Outlook 2020” Report Highlights:

  • US Transdermal Patch Market Overview
  • Generic & Branded Transdermal Patches
  • US Transdermal Patch Market: Value Chain Analysis
  • US Transdermal Patch Contract Manufacturing Organization
  • US Transdermal Patch Clinical Pipeline Insight by Company, Indication & Phase
  • US Transdermal Patch Clinical Pipeline: 55 Patches
  • Majority Patches in Preclinical Phase: 23 Patches
  • Marketed Transdermal Patch Clinical Insight by Company & Indication
  • Marketed Transdermal Patches in US: 32 Patches

Table of Contents

1. Introduction to Transdermal Patch

2. Classification of Transdermal Patches

  • 2.1. Single/ Multiple-Layer Drug-in-Adhesive
  • 2.2. Reservoir Transdermal Patches
  • 2.3. Matrix Based Transdermal Patches
  • 2.4. Vapor Patch
  • 2.5. Active and Passive Patch

3. Why There Exist Need for Transdermal Patches?

4. Mechanism of Transdermal Patch Drug Delivery

  • 4.1. Properties of Transdermal Therapeutics
  • 4.2. Components of Transdermal Patch
  • 4.3. Mechanism of Motion Sickness, Nicotine & Female Contraceptive Transdermal Patch

5. Transdermal Patch v/s Traditional Drug Delivery Methods

6. US Transdermal Patch Market Overview

  • 6.1. Current Market Scenario
  • 6.2. US Transdermal Patch Clinical Pipeline Overview

7. Generic & Branded Transdermal Patches

8. Value Chain Analysis for Transdermal Patch Market

  • 8.1. Research & Development
  • 8.2. Manufacturing
  • 8.3. Marketing & Distribution
  • 8.4. Price to End User

9. US Transdermal Patch Contract Manufacturing Organization (CMO)

10. US Transdermal Patch Market Opportunity Assessment

  • 10.1. Parkinson's Disease
  • 10.2. Alzheimer's Disease
  • 10.3. Female Contraceptive
  • 10.4. Nicotine Replacement Therapy
  • 10.5. Insulin
  • 10.6. Vaccine

11. US Transdermal Patch Market Dynamics

  • 11.1. Favorable Market Parameters
  • 11.2. Commercialization Challenges

12. US Transdermal Patch Market Future Prospects

13. US Transdermal Patch Clinical Pipeline by Company, Indication & Phase

  • 13.1. Research
  • 13.2. Preclinical
  • 13.3. Phase-I
  • 13.4. Phase-I/II
  • 13.5. Phase-II
  • 13.6. Phase-II/III
  • 13.7. Phase-III
  • 13.8. Preregistration
  • 13.9. Registered

14. Marketed Transdermal Patch Clinical Insight by Company & Indication

15. Discontinued & No Development Reported in US Transdermal Patch Clinical Pipeline

  • 15.1. No Development Reported
  • 15.2. Discontinued
  • 15.3. Marketed Withdrawal

16. Competitive Landscape

  • 16.1. 3M Pharmaceuticals
  • 16.2. Acrux
  • 16.3. Agile Therapeutics
  • 16.4. Allergan
  • 16.5. ANI Pharmaceuticals
  • 16.6. Antares Pharma
  • 16.7. Bayer HealthCare Pharmaceuticals
  • 16.8. Corium International
  • 16.9. Chase Pharmaceuticals
  • 16.10. DURECT Corporation
  • 16.11. Endo Pharmaceuticals
  • 16.12. Fempharm
  • 16.13. Hisamitsu Pharmaceutical
  • 16.14. Immune Pharmaceuticals
  • 16.15. Imprimis Pharmaceuticals
  • 16.16. Ipsen Bioscience
  • 16.17. Johnson & Johnson
  • 16.18. LaSalle Laboratories
  • 16.19. Lavipharm-increase
  • 16.20. MINRAD International
  • 16.21. NeurogesX
  • 16.22. Noven Pharmaceuticals
  • 16.23. NuPathe
  • 16.24. Nuvo Research
  • 16.25. Novartis
  • 16.26. Pain Therapeutics
  • 16.27. ProStrakan
  • 16.28. Purdue Pharma
  • 16.29. Sanofi
  • 16.30. Scilex Pharmaceuticals
  • 16.31. Senju Pharmaceutical
  • 16.32. Somerset Pharmaceuticals
  • 16.33. Teikoku Seiyaku
  • 16.34. Therapeutic Discovery Corporation
  • 16.35. Transdermal Delivery Solutions Corp
  • 16.36. UCB
  • 16.37. Xel Pharmaceuticals
  • 16.38. Zosano Pharma

List of Tables

  • Table 4-1: Transdermal Patches for Various Disease Indications
  • Table 6-1: Features Required in Transdermal Patches
  • Table 6-2: US - Different Transdermal Drug Delivery Systems Available in Market
  • Table 7-1: Similarities & Difference Between Generic & Branded Transdermal Patches
  • Table 7-2: US - Some Generic Transdermal Patches Available in Market
  • Table 8-1: Breakdown of Transdermal Patch Value Chain Analysis
  • Table 10-1: US - Estimated Adoption Rates for Parkinson's Disease Transdermal Patches , 2015-2020
  • Table 10-2: Description of Neupro Patch for Parkinson's Disease
  • Table 10-3: US - Estimated Adoption Rates for Transdermal Drug Delivery Systems for Alzheimer's Disease, 2015-2020
  • Table 10-4: Transdermal Patches for Alzheimer's Disease
  • Table 10-5: Description of Ortho Evra Contraceptive Patch
  • Table 10-6: Difference Between Generic & Branded Transdermal Contraceptive Products
  • Table 10-7: US-Estimated Adoption Rates for Transdermal Drug Delivery Systems for Diabetes Mellitus, 2015-2020
  • Table 10-8: US-Estimated Adoption rates for Transdermal Drug Delivery Systems for HIV, 2015-2020
  • Table 16-1: Pain Therapeutics Clinical Pipeline

List of Figures

  • Figure 1-1: Steps Involved in Transdermal Permeation
  • Figure 1-2: Ideal Properties of Transdermal Patch
  • Figure 2-1: Types of Commercially Available Transdermal Patch
  • Figure 4-1: Properties of Transdermal Therapeutics
  • Figure 4-2: Components of Transdermal Patch
  • Figure 4-3: Types of Permeation Enhancers
  • Figure 4-4: Schematic Representation of Iontophoresis
  • Figure 4-5: Mechanism of Scopolamine Transdermal Patch
  • Figure 4-6: Mechanism of Nicotine Transdermal Patch
  • Figure 4-7: Mechanism of Female Contraceptive Transdermal Patch
  • Figure 5-1: Issues with Traditional Drug Delivery Methods
  • Figure 5-2: Advantages of Transdermal Patch
  • Figure 5-3: Consistent Drug Supply by Transdermal Patch
  • Figure 6-1: Advantages of Transdermal Patches
  • Figure 6-2: Disadvantages of Transdermal Patches
  • Figure 6-3: US - Major Reasons Behind Growth of Transdermal Patches
  • Figure 6-4: US - Estimated Prescription Drug Spending (USD Billion), 2015-2020
  • Figure 6-5: US- Transdermal Drug Delivery System Market (US$ Billion), 2015-2020
  • Figure 6-6: US - Estimated Prescription Transdermal Patch Market by Volume (%), 2015 & 2020
  • Figure 6-7: US - Estimated Market Size of Prescription vs. Over-The-Counter Transdermal Patches (US$ Billion), 2015
  • Figure 6-8: US - Estimated Market Size of Prescription vs. Over-The-Counter Transdermal Patches (US$ Billion), 2020
  • Figure 6-9: US Transdermal Patch Pipeline by Phase (%), 2016
  • Figure 6-10: US Transdermal Patch Pipeline by Phase (Numbers), 2016
  • Figure 6-11: US Transdermal Patch Pipeline by Phase (%), 2016
  • Figure 6-12: US Transdermal Patch Pipeline by Phase (Numbers), 2016
  • Figure 7-1: Requirement in Generic Transdermal Patches
  • Figure 7-2: Reservations for Generic Transdermal Patches
  • Figure 7-3: US - Estimated Cost Comparison of Branded vs. Generic Contraceptive Patch
  • Figure 7-4: US - Estimated Cost Comparison of Cigarettes, Generic & Branded Nicotine Patches
  • Figure 8-1: Basic Features of Transdermal Patch Value Chain
  • Figure 8-2: Steps Involved in Transdermal Patch Manufacturing
  • Figure 9-1: Stages of Transdermal Patch Development
  • Figure 9-2: Advantages of Using Contract Manufacturing Organization for Transdermal Drug Delivery System
  • Figure 9-3: Requirements from Contract Manufacturing Organization for Transdermal Drug Delivery System
  • Figure 10-1: Potential Market Segments of Transdermal Drug Delivery Systems
  • Figure 10-2: US - Susceptibility of Parkinson Disease among Males and Females
  • Figure 10-3: US - Estimated Increase in Parkinson's Disease Incidences
  • Figure 10-4: US - Estimated Financial Impact of Parkinson's Disease on Economy (US$ Billion)
  • Figure 10-5: US - Parkinson's Disease Incidences, 2015-2020
  • Figure 10-6: US - Estimated Sales of Neupro Patch, 2104-2020
  • Figure 10-7: US - Estimated Worldwide Sales of Neupro, 2014 & 2015
  • Figure 10-8: US - Male & Female Suffering from Alzheimer's Disease (Million), 2015
  • Figure 10-9: US - Shares of Male & Female Suffering from Alzheimer's Disease (%), 2015
  • Figure 10-10: US - Percentage of Elderly People Suffering from Alzheimer's Disease, 2015
  • Figure 10-11: US - Estimated Increase in Alzheimer's Incidences, 2015, 2025 & 2050
  • Figure 10-12: US - Estimated Incidences of Alzheimer's Disease, 2015-2020
  • Figure 10-13: US - Exelon Patch Sales for Alzheimer's Disease, 2013 & 2014
  • Figure 10-14: Requirements of Female Contraceptive Transdermal Drug Delivery Systems
  • Figure 10-15: Benefits of Female Contraceptive Transdermal Drug Delivery System
  • Figure 10-16: US - Expected Revenues Generated by Xulane Patch (US$ Million), 2015-2020
  • Figure 10-17: US - Decrease in Number of Smokers due to Nicotine Patch, 2005 & 2013
  • Figure 10-18: Factors Responsible for Increased Consumption of Nicotine Patches
  • Figure 10-19: Rank of US among Different Diabetes Prone Countries
  • Figure 10-20: US - Estimated Increase in Diabetes Incidences, 2015-2020
  • Figure 10-21: Benefits of Insulin Transdermal Patch
  • Figure 10-22: Drawback of Insulin Transdermal Patch
  • Figure 10-23: Benefits of Vaccine Transdermal Patch
  • Figure 10-24: Drawbacks of Vaccine Transdermal Patch
  • Figure 10-25: US - Estimated HIV Incidences, 2015-2020
  • Figure 11-1: Transdermal Patch Market Favorable Factors
  • Figure 11-2: Transdermal Patch Market Commercialization Challenges
  • Figure 16-1: Acrux Clinical Pipeline
  • Figure 16-2: Agile Therapeutics Clinical Pipeline
  • Figure 16-3: Antares Pharma Clinical Pipeline
  • Figure 16-4: Corium International Clinical Pipeline
  • Figure 16-5: Durect Corporation Clinical Pipeline
  • Figure 16-6: Endo Pharmaceuticals Clinical Pipeline
  • Figure 16-7: Immune Pharmaceuticals Clinical Pipeline
  • Figure 16-8: Novartis Clinical Pipeline
  • Figure 16-9: Senju Pharmaceuticals Clinical Pipeline
  • Figure 16-10: Xel Pharamaceuticals Clinical Pipeline
  • Figure 16-11: Zosano Pharma Clinical Pipeline
Back to Top